SCHEMBL13214024

SCHEMBL13214024

Nc1c(S(=O)(=O)O)cc(Nc2ccc(Cl)cc2C(=O)O)c2c1C(=O)c1ccccc1C2=O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P2RY4 P51582 10/20 0.70
▸ P2RY12 Q9H244 4/20 0.70
▸ P2RY2 P41231 3/20 0.64
▸ GNG2 P59768 5/20 0.60
▸ GNB1 P62873 5/20 0.60
▸ PHLPP2 Q6ZVD8 2/20 0.58
▸ CYP1A2 P05177 2/20 0.55
▸ CYP2C9 P11712 2/20 0.55
▸ ALOX15 P16050 2/20 0.55
▸ HSD17B10 Q99714 2/20 0.55
▸ ALDH1A1 P00352 1/20 0.55
▸ CYP3A4 P08684 1/20 0.55
▸ HPGD P15428 1/20 0.55
▸ MAPK1 P28482 1/20 0.55
▸ CYP2C19 P33261 1/20 0.55
▸ HIF1A Q16665 1/20 0.55
▸ HPGDS O60760 1/20 0.54
▸ USP2 O75604 1/20 0.52
▸ APEX1 P27695 1/20 0.52
▸ CHAT P28329 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3032970 0.99 P2RY4 (0.68) P2RY4P2RY12P2RY2GNG2GNB1
SCHEMBL13214025 0.93 P2RY4 (0.81) P2RY4P2RY12P2RY2GNG2GNB1
SCHEMBL3025537 0.92 P2RY4 (0.80) P2RY4P2RY12P2RY2GNG2GNB1
SCHEMBL11425002 0.90 GNG2 (0.68) P2RY4P2RY12P2RY2GNG2GNB1
SCHEMBL3032967 0.89 P2RY4 (0.86) P2RY4P2RY12P2RY2CDK2P2RY1
SCHEMBL13214031 0.89 P2RY4 (0.79) P2RY4P2RY12P2RY2GNG2GNB1
SCHEMBL29355096 0.88 P2RY2 (0.81) P2RY4P2RY12P2RY2GNG2GNB1
SCHEMBL19948045 0.88 P2RY2 (0.81) P2RY4P2RY12P2RY2GNG2GNB1
SCHEMBL3028638 0.88 P2RY4 (0.78) P2RY4P2RY12P2RY2GNG2GNB1
SCHEMBL11601364 0.88 GNG2 (0.67) P2RY4P2RY12P2RY2GNG2GNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2129653-B1 NOVEL P2Y12 RECEPTOR ANTAGONISTS Rheinische Friedrich-Wilhelms-Universität Bonn (DE) 2017-05-17 — — EP disclosed
US-20100210654-A1 NOVEL P2Y12 RECEPTOR ANTAGONISTS RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITÄT BONN (DE) 2010-08-19 — — US disclosed
US-20100210654-A1 NOVEL P2Y12 RECEPTOR ANTAGONISTS RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITÄT BONN (DE) 2010-08-19 — — US disclosed
WO-2008107211-A2 NOVEL P2Y12 RECEPTOR ANTAGONISTS RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITÄT BONN (DE) 2008-09-12 — — WO disclosed
EP-1967513-A1 Novel P2Y12 receptor antagonists Rheinische Friedrich-Wilhelms-Universität Bonn (DE) 2008-09-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210654-A1 NOVEL P2Y12 RECEPTOR ANTAGONISTS P2RY12, P2RY11, P2RY13 P2RY4 8/4885P2RY12 1/4885P2RY2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback